Molecular Identification and Antifungal Susceptibility of Fusarium spp. Clinical Isolates
Mycoses · 2025
DOI: 10.1111/myc.70012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mycoses, 2025. Verfasst von Carla M Román-Montes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Microbiology Laboratory, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Hauptthemen laut MEDLINE: Fusarium, Fusariosis, Antifungal Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Accurate identification of Fusarium species requires molecular identification. Treating fusariosis is challenging due to widespread antifungal resistance, high rates of treatment failure, and insufficient information relating antifungal susceptibility to the clinical outcome. Despite recent outbreaks in Mexico, there is limited information on epidemiology and antifungal susceptibility testing (AST).
Objectives
We aimed to analyse the distribution of Fusarium species from a referral centre in Mexico with DNA sequencing and to describe AST to the clinical outcome.
Methods
We conducted a retrospective study on clinical isolates of Fusarium . They were identified by translation elongation factor‐1α gene amplification and sequencing. AST was performed to determine minimal inhibitory concentrations (MICs).
Results
A total of 35 Fusarium isolates from 26 patients were included. The most common was Fusarium solani species complex (FSSC) in 51.5%, of which Fusarium petroliphilum and Fusarium oxysporum species complex were the most frequent with 37% and 20%, respectively. AST did not show MICs above the epidemiological cut‐off value. Fusariosis was diagnosed in 19 patients, mostly with hematologic neoplasm; the overall mortality rate was 32%.
Conclusions
Fusarium petroliphilum from the FSSC was found most frequently. Elevated mortality and MICs for all tested antifungals were found, with higher MIC50 among F. solani SC than F. oxysporum SC or F. fujikuroi SC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Microbiology Laboratory, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
- Infectious Diseases Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
- General Direction, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
ORCID-Profile: Carla M Román-Montes, Axel Cervantes Sánchez
Zitieren
APA
Román-Montes, C. M., González-Lara, F., Diaz-Lomelí, P., Sánchez, A. C., Rangel-Cordero, A., Sifuentes-Osornio, J., Ponce-de-León, A., & Martínez-Gamboa, A. (2025). Molecular Identification and Antifungal Susceptibility of Fusarium spp. Clinical Isolates. Mycoses. https://doi.org/10.1111/myc.70012
Vancouver
Román-Montes CM, González-Lara F, Diaz-Lomelí P, Sánchez AC, Rangel-Cordero A, Sifuentes-Osornio J, et al. Molecular Identification and Antifungal Susceptibility of Fusarium spp. Clinical Isolates. Mycoses. 2025. doi:10.1111/myc.70012
BibTeX
@article{RomnMontes2025,
author = {Román-Montes, Carla M and González-Lara, Fernanda and Diaz-Lomelí, Paulette and Sánchez, Axel Cervantes and Rangel-Cordero, Andrea and Sifuentes-Osornio, José and Ponce-de-León, Alfredo and Martínez-Gamboa, Areli},
title = {Molecular Identification and Antifungal Susceptibility of Fusarium spp. Clinical Isolates},
journal = {Mycoses},
year = {2025},
doi = {10.1111/myc.70012}
}
EUVIMED